Granules India’s arm concludes USFDA audit with three minor observations

31 Jan 2022 Evaluate

Granules India’s wholly-owned foreign subsidiary -- Granules Pharmaceuticals, Inc. (GPI) has concluded USFDA audit with three minor observations. GPI located in Chantilly, Virginia, USA had undergone a Preapproval Inspection (PAI) by the US Food and Drug Administration (USFDA) from January 24, 2022 to January 28, 2022. The audit is a PAI for two of its product applications filed from this facility.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

611.00 4.90 (0.81%)
06-Jan-2025 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.50
Dr. Reddys Lab 1346.95
Cipla 1494.15
Lupin 2354.05
Zydus Lifesciences 959.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.